2016 sales of the Galenica Group
Thursday, 19 January 2017
Galenica 2016: Further increase in sales and confirmation of profit forecasts
The Galenica Group continued its dynamic growth in 2016, increasing consolidated net sales by 8.6% to CHF 4,118.4 million. Both Business units, Vifor Pharma and Galenica Santé, con-tributed to this growth.
Management confirms the profit and EBIT forecasts for financial year 2016 communicated in October 2016.
The Galenica Group confirms its intention to develop Vifor Pharma and Galenica Santé into two independent listed companies in 2017. A separate press release has been issued today on the status of the current preparatory work.
Vifor Pharma: sales in excess of CHF 1 billion
2016 was another successful year for Vifor Pharma. Net sales increased by 24.8% to CHF 1,167.0 million. This growth was achieved organically.
Sales of iron deficiency product Ferinject®/Injectafer® generated by Vifor Pharma affiliates and partners once again grew impressively all over the world, totalling CHF 349.5 million (+39.3%). The distribution agreement with Roche for Mircera® contributed sales of CHF 328.6 million. The combination with Relypsa, which was completed according to schedule in the second half of the year, makes Vifor Pharma a significant player in cardio-renal care in the USA.
Galenica Santé: growth through innovations and new customers
With an increase in sales of 3.2% to CHF 3,008.9 million, Galenica Santé performed well in the market in 2016. CHF 1,437.0 million (+3.1%) of this was contributed by the Health & Beauty segment, and CHF 2,328.9 million (+3.8%) by the Services segment. The growth is based on the expansion of the pharmacy network, innovative new offerings and the acquisition of new cus-tomers. For example, Galenica Santé complemented its product range with exclusive beauty and grooming products from well-known partners such as the dermo-cosmetics laboratory Pierre Fabre. In order to further increase efficiency, cooperation was more closely coordinated across all segments and areas of Galenica Santé, while the Galexis logistics centre in Niederbipp was expanded to ensure the timely processing of even higher volumes.
Other press releases
- Tuesday, 8 August 2017
- Wednesday, 7 June 2017
Tel. +41 58 852 85 17
Mobile +41 79 371 77 24
Fax +41 58 852 85 58
Tel. +41 58 852 85 29
Fax +41 58 852 85 35